COVID-19
In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.
Ridgeback Therapeutics will launch two mid-stage programs assessing the efficacy of its antiviral candidate EIDD-2801 as a treatment for COVID-19.
As companies scramble to develop a vaccine against the SARS-CoV-2 virus, a team of husband and wife researchers have found that the measles, mumps, rubella (MMR) vaccine can reduce the symptoms of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
The TACTIC-E trial will investigate the safety and efficacy of experimental therapies designed to prevent and treat life-threatening complications associated with COVID-19 in hospitalized patients who are at early stages of the disease.
UV-C light has been used as a disinfectant against viruses and bacteria for more than 40 years. Now, researchers at Boston University and Signify (formerly Phillips) have confirmed that it also effectively eradicates the SARS-CoV-2 virus.
It was a busy week for clinical trial announcements. Here’s a look.
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
A new study published on Wednesday in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.
PRESS RELEASES